Prostate cancer-associated tumor antigens

Prostate cancer-associated tumor antigens (PCATAs) are a heterogeneous group of proteins that are overexpressed or specifically expressed in prostate tissue and malignant cells. Key members of this group include Prostate-Specific Membrane Antigen (PSMA), Prostate-Specific Antigen (PSA), and Prostatic Acid Phosphatase (PAP) (UniProt Q04609, P07288, P15309). These antigens serve as vital targets for both diagnostic imaging and therapeutic modalities, such as radioligand therapy and immunotherapy. For instance, PSMA is a transmembrane glycoprotein with carboxypeptidase activity that is highly upregulated in metastatic castration-resistant prostate cancer, making it an ideal target for agents like Lutetium (177Lu) vipivotide tetraxetan (Sartor et al., 2021). Similarly, PAP is the target for Sipuleucel-T, the first FDA-approved autologous cellular immunotherapy for prostate cancer (Kantoff et al., 2010). Biologically, these antigens vary in function, ranging from enzymatic activity in the seminal fluid to nutrient transport and cell signaling within the tumor microenvironment. In clinical practice, PSA is the most widely used biomarker for screening and monitoring treatment response, although its specificity for cancer remains a subject of debate (NIH, 2023). While these antigens provide a pathway for precision medicine, challenges such as intra-patient tumor heterogeneity and potential off-target effects in healthy tissues like the salivary glands remain critical considerations in drug development.

Other names

Prostate-associated antigensProstate tumor antigensProstate cancer TAAsProstate-specific antigens

Therapeutic strategies include radioligand therapy (targeted delivery of beta-emitters), autologous cellular immunotherapy (activation of T-cells against specific antigens), and monoclonal antibodies for imaging or drug delivery (Sartor et al., 2021; Kantoff et al., 2010).